Skip to main content
. 2006 Nov 20;51(2):429–437. doi: 10.1128/AAC.01032-06

TABLE 3.

Cross-resistance of 94 clinical HIV-1 isolates between efavirenz and VRX-480773

Efavirenz fold change in EC50 value No. (%) of isolates with VRX-480773 fold change in EC50 value ofa:
<10 >10
<10 24 (22.4) 3 (0.9)
>10 28 (45.9) 39 (19.1)
a

Numbers in parentheses correspond to the percentage of total isolates in the Stanford database.